ONC
NEUTRAL
$319.94
Live
BeOne Medicines AG · NASDAQ
Target $408.2
(+27.6%)
$218.31
52W Range
$385.22
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 16, 2026
Market cap
$36.75B
P/E
124.98
ROE
7.5%
Profit margin
5.4%
Debt/Equity
0.25
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
ONC exhibits strong operational health with a Piotroski F-Score of 7/9 and a robust balance sheet characterized by low debt (D/E 0.25) and high liquidity. However, there is a severe disconnect between the current market price ($319.94) and deterministic value metrics, with the Graham Number ($47.6) and Intrinsic Value ($17.92) suggesting massive overvaluation. While the company has successfully transitioned from deep historical losses to profitability and maintains strong revenue growth (32.8%), aggressive insider selling by the CEO and a bearish technical trend offset the 'Strong Buy' analyst consensus.
Key Strengths
Strong financial health (Piotroski F-Score 7/9)
Excellent liquidity with a Current Ratio of 3.41
High gross margins (87.49%) typical of high-value biotech
Successful pivot to profitability from a history of net losses
Strong top-line revenue growth (32.8% YoY)
Key Risks
Extreme valuation premium (P/E 124.98 vs. Intrinsic Value $17.92)
Bearish insider sentiment with significant CEO divestment
High volatility in quarterly earnings surprises
Technical trend is currently 0/100 (Bearish)
Heavy reliance on future growth to justify current price
AI Fair Value Estimate
Based on comprehensive analysis
$82.5
-74.2% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
48
Moderate
15
75
60
90
0
AI Verdict
Speculative Growth
Key drivers: Operational turnaround, Balance sheet strength, Valuation bubble risk, Insider divergence
Confidence
90%
Value
15/100
Ref P/E, PEG, Graham Number
Positives
- Forward P/E (34.45) is significantly lower than trailing P/E
Watchpoints
- Price is ~6.7x the Graham Number
- Price is ~17.8x the Intrinsic Value
- P/B ratio of 8.13 is elevated
Future
75/100
Ref Growth rates
Positives
- Consistent revenue growth >30%
- Positive trajectory in EPS progression
- Strong analyst price targets ($408.20)
Watchpoints
- Recent Q/Q EPS growth decline (-46.8%)
Past
60/100
Ref Historical trends
Positives
- Successful transition from loss-making to profit-making
Watchpoints
- Long history of negative earnings (2020-2024)
Health
90/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Piotroski F-Score 7/9
- Very low Debt/Equity (0.25)
- Strong Quick Ratio (2.97)
Watchpoints
- Altman Z-Score not provided
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend payments
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$319.94
Analyst Target
$408.2
Upside/Downside
+27.6%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ONC and closest competitors.
Updated 2026-04-15
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ONC
BeOne Medicines AG
Primary
|
+4.7% | +20.8% | +34.0% | +1.2% | +10.5% | +2.5% |
|
A
Agilent Technologies, Inc.
Peer
|
+11.4% | -11.3% | -10.7% | +12.8% | -2.2% | -3.3% |
|
MDLN
Medline Inc.
Peer
|
+15.2% | +15.2% | +15.2% | +15.2% | +13.9% | +7.6% |
|
ALC
Alcon Inc.
Peer
|
+8.8% | +9.9% | -9.6% | -12.6% | +0.1% | +1.6% |
|
INSM
Insmed Incorporated
Peer
|
+402.3% | +817.7% | +138.9% | -4.6% | +11.1% | -4.7% |
ONC
BeOne Medicines AG
Primary
5Y
+4.7%
3Y
+20.8%
1Y
+34.0%
6M
+1.2%
1M
+10.5%
1W
+2.5%
A
Agilent Technologies, Inc.
Peer
5Y
+11.4%
3Y
-11.3%
1Y
-10.7%
6M
+12.8%
1M
-2.2%
1W
-3.3%
MDL
Medline Inc.
Peer
5Y
+15.2%
3Y
+15.2%
1Y
+15.2%
6M
+15.2%
1M
+13.9%
1W
+7.6%
ALC
Alcon Inc.
Peer
5Y
+8.8%
3Y
+9.9%
1Y
-9.6%
6M
-12.6%
1M
+0.1%
1W
+1.6%
INS
Insmed Incorporated
Peer
5Y
+402.3%
3Y
+817.7%
1Y
+138.9%
6M
-4.6%
1M
+11.1%
1W
-4.7%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
124.98
Forward P/E
34.45
PEG Ratio
N/A
P/B Ratio
8.13
P/S Ratio
6.88
EV/Revenue
85.72
EV/EBITDA
791.24
Market Cap
$36.75B
Profitability
Profit margins and return metrics
Profit Margin
5.37%
Operating Margin
12.35%
Gross Margin
87.49%
ROE
7.46%
ROA
3.96%
Growth
Revenue and earnings growth rates
Revenue Growth
+32.8%
Earnings Growth
N/A
Q/Q Revenue Growth
+32.84%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.25
Low debt
Current Ratio
3.41
Strong
Quick Ratio
2.97
Excellent
Cash/Share
$3.15
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$1.5B
Gross Margin
90.5%
Op. Margin
12.4%
Net Margin
4.4%
Total Assets
$8.2B
Liabilities
$3.8B
Equity
$4.4B
Debt/Equity
0.88x
Operating CF
$0.4B
CapEx
$-0.0B
Free Cash Flow
$0.4B
FCF Yield
91%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-06
$N/A
2026-02-26
$0.58
-55.3% surprise
2025-11-06
$1.09
+27.0% surprise
2025-08-06
$0.84
+224.3% surprise
Healthcare Sector Comparison
Comparing ONC against 421 companies in the Healthcare sector
(25 bullish, 134 neutral, 262 bearish)
P/E Ratio
124.98
This Stock
vs
89.02
Sector Avg
+40.4%
(Expensive)
Return on Equity (ROE)
7.46%
This Stock
vs
-100.15%
Sector Avg
-107.4%
(Below Avg)
Profit Margin
5.37%
This Stock
vs
-13.63%
Sector Avg
-139.4%
(Weaker)
Debt to Equity
0.25
This Stock
vs
3.22
Sector Avg
-92.2%
(Less Debt)
Revenue Growth
32.8%
This Stock
vs
121.05%
Sector Avg
-72.9%
(Slower)
Current Ratio
3.41
This Stock
vs
4.55
Sector Avg
-25.1%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ONC
BeOne Medicines AG
|
NEUTRAL | $36.75B | 124.98 | 7.5% | 5.4% | $319.94 | |
|
A
Agilent Technologies, Inc.
|
NEUTRAL | $38.29B | 30.28 | 20.6% | 18.8% | $135.05 | Compare |
|
MDLN
Medline Inc.
|
NEUTRAL | $38.33B | 33.02 | 6.5% | 4.1% | $47.22 | Compare |
|
ALC
Alcon Inc.
|
NEUTRAL | $39.59B | 38.6 | 4.8% | 10.3% | $80.29 | Compare |
|
INSM
Insmed Incorporated
|
BEARISH | $33.42B | - | -249.3% | -210.5% | $154.81 | Compare |
ONC
BeOne Medicines AG
NEUTRAL
Mkt Cap
$36.7B
P/E
125.0
ROE
7.5%
Price
$319.94
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-08 | LEE CHAN HENRY | General Counsel | Sale | 332 | $103,448 |
| 2026-04-08 | LEE CHAN HENRY | General Counsel | Option Exercise | 332 | $63,598 |
| 2026-03-11 | LEE CHAN HENRY | General Counsel | Sale | 341 | $102,300 |
| 2026-03-11 | LEE CHAN HENRY | General Counsel | Option Exercise | 341 | $65,348 |
| 2026-02-04 | LEE CHAN HENRY | General Counsel | Sale | 1,660 | $580,197 |
| 2026-02-04 | LEE CHAN HENRY | General Counsel | Option Exercise | 1,660 | $317,721 |
| 2026-01-07 | LEE CHAN HENRY | General Counsel | Sale | 664 | $220,289 |
| 2026-01-07 | LEE CHAN HENRY | General Counsel | Option Exercise | 664 | $127,196 |
| 2025-12-16 | OYLER JOHN VICTOR | Chief Executive Officer | Sale | 100,000 | $30,659,419 |
| 2025-12-11 | LEE CHAN HENRY | General Counsel | Sale | 664 | $213,569 |
| 2025-12-11 | LEE CHAN HENRY | General Counsel | Option Exercise | 664 | $127,196 |
| 2025-11-26 | SANDERS CORAZON CORSEE D | Director | Sale | 2,627 | $895,534 |
| 2025-11-26 | SANDERS CORAZON CORSEE D | Director | Option Exercise | 2,627 | $417,772 |
| 2025-11-17 | WU XIAOBIN | President | Sale | 3,991 | $1,518,303 |
| 2025-11-13 | WU XIAOBIN | President | Sale | 16,009 | $5,846,820 |
LEE CHAN HENRY
General Counsel
2026-04-08
332 shares
·
$103,448
LEE CHAN HENRY
General Counsel
2026-04-08
332 shares
·
$63,598
LEE CHAN HENRY
General Counsel
2026-03-11
341 shares
·
$102,300
LEE CHAN HENRY
General Counsel
2026-03-11
341 shares
·
$65,348
LEE CHAN HENRY
General Counsel
2026-02-04
1,660 shares
·
$580,197
LEE CHAN HENRY
General Counsel
2026-02-04
1,660 shares
·
$317,721
LEE CHAN HENRY
General Counsel
2026-01-07
664 shares
·
$220,289
LEE CHAN HENRY
General Counsel
2026-01-07
664 shares
·
$127,196
OYLER JOHN VICTOR
Chief Executive Officer
2025-12-16
100,000 shares
·
$30,659,419
LEE CHAN HENRY
General Counsel
2025-12-11
664 shares
·
$213,569
LEE CHAN HENRY
General Counsel
2025-12-11
664 shares
·
$127,196
SANDERS CORAZON CORSEE D
Director
2025-11-26
2,627 shares
·
$895,534
SANDERS CORAZON CORSEE D
Director
2025-11-26
2,627 shares
·
$417,772
WU XIAOBIN
President
2025-11-17
3,991 shares
·
$1,518,303
WU XIAOBIN
President
2025-11-13
16,009 shares
·
$5,846,820
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
26 analysts
Wolfe Research
2026-03-27
Outperform
Jefferies
2026-03-16
Buy
Hold
RBC Capital
2026-02-27
Outperform
Outperform
Truist Securities
2026-02-27
Buy
Buy
Guggenheim
2026-02-27
Buy
Buy
Barclays
2026-02-27
Overweight
Overweight
Barclays
2026-02-04
Overweight
Overweight
Truist Securities
2025-11-24
Buy
RBC Capital
2025-11-18
Outperform
Outperform
Citigroup
2025-11-10
Buy
Buy
Past News Coverage
Recent headlines mentioning ONC from our newsroom.
Newest → oldest
No matching news yet.